Bivin & Associates’s Omnicell OMCL Stock Holding History

Bivin & Associates’s Portfolio OMCL Stock Details OMCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10	Closed	-$1K	–	353
2022 Q1	$1K	Hold	10	–	–	﹤0.01%	314
2021 Q4	$2K	Buy	+10	New	+$1.74K	﹤0.01%	258

Other funds holding OMCL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bivin & Associates's OMCL Position: Q2 2022 in Review

Bivin & Associates sold out of Omnicell (OMCL) in Q2 2022, closing a stake of 10 shares — an estimated $1K sold.

Bivin & Associates first reported a position in OMCL in Q4 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 385 funds tracked by Wall St. Rank hold OMCL as of Q2 2022.

Bivin & Associates reported no remaining Omnicell position as of Q2 2022 after selling out during the quarter.
Bivin & Associates sold 10 Omnicell shares in Q2 2022, an estimated $1K.
Bivin & Associates first reported a position in Omnicell in Q4 2021 and held it in 2 quarters.
Bivin & Associates's Omnicell position peaked at $2K in Q4 2021.
385 funds tracked by Wall St. Rank held Omnicell as of Q2 2022.

Based on Bivin & Associates's 13F filing for Q2 2022, filed 11 Aug 2022.